Literature DB >> 30448387

Development of covalent NLRP3 inflammasome inhibitors: Chemistry and biological activity.

Massimo Bertinaria1, Simone Gastaldi2, Elisabetta Marini2, Marta Giorgis2.   

Abstract

The NOD-like receptor family, pyrin domain-containing 3 (NLRP3) inflammasome is the best recognized and most widely implicated regulator of caspase-1 activation. It is a key regulator of innate immune response and is involved in many pathophysiological processes. Recent evidences for its inappropriate activation in autoinflammatory, autoimmune, as well as in neurodegenerative diseases attract a growing interest toward the development of small molecules NLRP3 inhibitors. Based on the knowledge of biochemical and structural aspects of NLRP3 activation, one successful strategy in the identification of NLRP3 inhibitors relies on the development of covalent irreversible inhibitors. Covalent inhibitors are reactive electrophilic molecules able to alkylate nucleophiles in the target protein. These inhibitors could ensure good efficacy and prolonged duration of action both in vitro and in vivo. In spite of these advantages, effects on other signalling pathways, prone to alkylation, may occur. In this review, we will illustrate the chemistry and the biological action of the most studied covalent NLRP3 inhibitors developed so far. A description of what we know about their mechanism of action will address the reader toward a critical understanding of NLRP3 inhibition by electrophilic compounds.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Covalent drugs; Drug design; Irreversible inhibitors; NLRP3 inflammasome; NLRP3 inhibitors

Mesh:

Substances:

Year:  2018        PMID: 30448387     DOI: 10.1016/j.abb.2018.11.013

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  7 in total

Review 1.  Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease.

Authors:  Antonio Abbate; Stefano Toldo; Carlo Marchetti; Jordana Kron; Benjamin W Van Tassell; Charles A Dinarello
Journal:  Circ Res       Date:  2020-04-23       Impact factor: 17.367

Review 2.  The Role of Inflammasome-Dependent and Inflammasome-Independent NLRP3 in the Kidney.

Authors:  Yang Gyun Kim; Su-Mi Kim; Ki-Pyo Kim; Sang-Ho Lee; Ju-Young Moon
Journal:  Cells       Date:  2019-11-05       Impact factor: 6.600

Review 3.  ATP-Binding and Hydrolysis in Inflammasome Activation.

Authors:  Christina F Sandall; Bjoern K Ziehr; Justin A MacDonald
Journal:  Molecules       Date:  2020-10-07       Impact factor: 4.411

4.  Inflammasome Inhibitors.

Authors:  Massimo Bertinaria
Journal:  Molecules       Date:  2021-11-16       Impact factor: 4.411

5.  Exploring the mechanism of action of dapansutrile in the treatment of gouty arthritis based on molecular docking and molecular dynamics.

Authors:  Jun-Feng Cao; Mei Wu; Shengyan Chen; Hengxiang Xu; Yunli Gong; Lixin Zhang; Qilan Zhang; Xiao Zhang
Journal:  Front Physiol       Date:  2022-08-29       Impact factor: 4.755

Review 6.  Importance of NLRP3 Inflammasome in Abdominal Aortic Aneurysms.

Authors:  Jinyun Shi; Jia Guo; Zhidong Li; Baohui Xu; Masaaki Miyata
Journal:  J Atheroscler Thromb       Date:  2021-03-06       Impact factor: 4.928

7.  Chemical Modulation of the 1-(Piperidin-4-yl)-1,3-dihydro-2H-benzo[d]imidazole-2-one Scaffold as a Novel NLRP3 Inhibitor.

Authors:  Simone Gastaldi; Valentina Boscaro; Eleonora Gianquinto; Christina F Sandall; Marta Giorgis; Elisabetta Marini; Federica Blua; Margherita Gallicchio; Francesca Spyrakis; Justin A MacDonald; Massimo Bertinaria
Journal:  Molecules       Date:  2021-06-29       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.